A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer
Latest Information Update: 16 Aug 2023
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Niraparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 11 Aug 2023 Status changed from active, no longer recruiting to completed.
- 09 Feb 2023 Planned End Date changed from 28 Apr 2023 to 1 Jul 2023.
- 09 Feb 2023 Planned primary completion date changed from 28 Apr 2023 to 1 Jul 2023.